[January 10, 2013]

Research and Markets: Non-Small-Cell Lung Cancer (Event Driven) - Drug Development Moving Towards a Personalised Medicine Approach

Research and Markets (http://www.researchandmarkets.com/research/7blrcx/nonsmallcell) has announced the addition of Decision Resources, Inc's new report "Non-Small-Cell Lung Cancer (Event Driven)" to their offering.

Drug development for non-small-cell lung cancer (NSCLC) is increasingly moving toward a personalized medicine approach. The management of NSCLC patients no longer focuses on only individualized treatment based on histological subtypes but is instead evolving into patient management increasingly based on specific molecular drivers.

Harnessing the power of a clinicaldevelopment strategy that incorporates a validated biomarker and codevelopment of a drug and companion diagnostic will be the most promising path forward. With numerous unidentified molecular drivers for NSCLC and a high level of unmet need among NSCLC patients with squamous-cell tumors and KRAS-mutated tumors, there is significant commercial opportunity for innovative new treatments for NSCLC.

Key Topics Covered:

Executive Summary

What are the key parameters of the non-small-cell lung cancer (NSCLC) market

What factors are driving the market for NSCLC therapies

What factors are constraining the market for NSCLC therapies

What are the drug development activities of note in NSCLC

What do the experts say

What key challenges and opportunities remain

Etiology and Pathophysiology

Epidemiology and Patient Populations

Current Therapy and Medical Practice

Unmet Needs

Emerging Therapies

Market Outlook

For more information visit http://www.researchandmarkets.com/research/7blrcx/nonsmallcell

Source (News - Alert): Decision Resources, Inc

[ Back To Technology News's Homepage ]